554MO Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-type patients with initially unresectable colorectal liver metastases: The TRICE randomized clinical trial

• DOI: 10.1016/j.annonc.2023.09.1745
• Publication Date: 2023-10-20T12:25:21Z
• Authors: Y. Li; D. Wang; C. Ren; S-S. Li; W. Pat Fong; X. Wu; J. Xiao; Y. Yuan; B-K. Li; P-R. Ding; Z. Wang; F. Wang; Z. Pan; G. Chen; X-Z. Wang; L-Y. Wang; T. Chen; T. Liu; Y. Yuan; R-H. Xu
• Keywords: FOLFOX; Clinical endpoint; Progression-free survival